Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

State GOP Leaders Press Congress to Revamp Health Care Law

State Republican leaders are ratcheting up the pressure on Congress to overhaul the Affordable Care Act if the Supreme Court this month rules that subsidies on the federal exchange are invalid. Republicans from 33 states have written to Congress as part of a coordinated message urging federal legislators to develop a plan that would free […]

Read More »

Lions Health 2015

Results are in from Lions Health 2015, taking place June 19th-20th in Cannes, France. Cannes Lions is the world’s largest yearly awards show and festival for professionals in the creative communications industry.  Lions Health is the global creative festival for the healthcare communications arena, which includes the world’s largest healthcare communications awards and is the […]

Read More »

Center for Medicine in the Public Interest Questions Accuracy and Utility of “Cost Calculator” from a Leading Cancer Center

NEW YORK–(BUSINESS WIRE)–The Center for Medicine in the Public Interest (CMPI) today criticized a so-called cost calculator for cancer medications as inaccurate and potentially dangerous. An article in the Wall Street Journal says, “Memorial Sloan Kettering Cancer Center in New York has created an interactive calculator that compares the cost of more than 50 cancer […]

Read More »

Many psoriasis patients have undiagnosed arthritis

Up to 15 percent of people with psoriasis have undiagnosed arthritis that’s related to the chronic itchy skin condition, according to a new review. “The important takeaway point for a lay audience would be that further education is needed for patients with psoriasis about the potential that they may develop psoriatic arthritis,” said Dr. Abby […]

Read More »

Discovery Promises New Treatments To Thwart Colon Cancer

MEMPHIS, Tenn., June 19, 2015 /PRNewswire-USNewswire/ — Scientists at St. Jude Children’s Research Hospital have discovered how an immune system protein, called AIM2 (Absent in Melanoma 2), plays a role in determining the aggressiveness of colon cancer. They found that AIM2 deficiency causes uncontrolled proliferation of intestinal cells. Surprisingly, they also discovered that AIM2 influences the […]

Read More »

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab)

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission has approved Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced (unresectable or metastatic) melanoma in adults, regardless of BRAF status. Today’s approval allows for the marketing of Opdivo in all 28 Member States of the EU. It follows an accelerated […]

Read More »

Amgen’s cancer drug meets main goal in late-stage study

Amgen Inc said its drug met the main goal of improving overall survival in metastatic colorectal cancer patients who have not responded to chemotherapy. The late-stage study was testing the drug, Vectibix, in combination with best supportive care (BSC), compared with BSC alone. Patients who received 6 mg/kg of the drug every 14 days and […]

Read More »

CDC Foundation, Pfizer and CDC Partner to Develop Longitudinal Data Collection System for Sickle Cell Disease

Effort With CDC to Collect, Analyze and Disseminate Much-Needed Sickle Cell Information ATLANTA, GA–(Marketwired – June 19, 2015) – Sickle cell disease (SCD), estimated to affect nearly 100,000 Americans, is the most common inherited blood disorder in the United States and the estimated cost of care for sickle cell disease is approximately $1.1 billion dollars […]

Read More »

Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has completed the purchase of 4.61 percent of all outstanding shares of Mylan N.V. (NASDAQ: MYL), which will enable Teva to commence proceedings before the Dutch Enterprise Chamber, should it become necessary. Teva has advised Stichting Preferred Shares Mylan that if the […]

Read More »

PlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect Broader Rare Disease Commitment

NEW YORK, NY–(Marketwired – June 19, 2015) – Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases Established next generation AAV-based gene therapy platform led by four rare, autosomal recessive (inherited) orphan pediatric disease product candidates in development Acquired CRISPR-Cas9 gene-editing system with first lead […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom